Ellipsis Health is pioneering a new clinical standard in mental health care by turning the human voice into an objective signal for emotional and behavioral wellbeing. The company's proprietary Empathy Engine is built on patented vocal biomarker technology and trained on millions of live clinical patient calls, allowing it to detect subtle vocal patterns that correlate with conditions like depression, anxiety, and stress. Rather than relying solely on self-reported questionnaires, Ellipsis adds a continuous, voice-based layer of measurement that can support early detection and triage.
The company's flagship product is Sage, described as an emotionally intelligent AI Care Manager. Sage supports patients with complex physical, behavioral, and social needs, engaging them empathetically while extending the capacity of human care teams. By automating routine outreach and surfacing patients who need attention, Sage helps care-management organizations cover more people with the same staff, reduce operating costs, and intervene earlier when someone is struggling.
Ellipsis Health is positioned for the enterprise side of healthcare, selling to health systems, payers, and care-management organizations that are under pressure to manage rising behavioral-health needs amid clinician shortages. Its voice-first approach is designed to integrate into existing clinical workflows and telephonic care programs, where the technology can run quietly in the background of patient conversations.
In June 2025, Ellipsis Health closed a $45 million Series A led by Salesforce, Khosla Ventures, and CVS Health Ventures, with participation from Mitsui Global Investment, Collier, E12, and AME Cloud Ventures. The funding accelerates Sage's adoption across providers and payers while the company expands its AI capabilities and clinical integrations. Building on an earlier $26 million round, Ellipsis Health is scaling its mission to deliver empathetic, AI-driven mental health support at population scale.